Biomarker Analysis Services for Cytokine Release Syndrome
Protheragen offers specialized biomarker analysis services dedicated to advancing research and development in Cytokine Release Syndrome (CRS). Our comprehensive biomarker panel is designed to provide a deep understanding of CRS pathophysiology, supporting the identification and characterization of molecular targets relevant to drug discovery and preclinical development. Please note that all our services are exclusively focused on research and exploratory drug development through the preclinical stage; we do not provide clinical diagnostic services.
Effective therapeutic intervention for Cytokine Release Syndrome begins with robust biomarker discovery and identification. Protheragen’s biomarker discovery services integrate advanced screening platforms and validation workflows to uncover molecules associated with CRS pathogenesis. Our approach includes high-throughput screening of candidate genes, proteins, and signaling molecules, followed by rigorous validation steps to confirm their relevance. This systematic process underpins target identification, mechanism-of-action studies, and the rational design of therapeutic strategies for CRS drug development.
Multi Omics: We employ a cutting-edge multi-omics strategy encompassing genomics, transcriptomics, proteomics, and metabolomics to enable a comprehensive study of biological systems implicated in Cytokine Release Syndrome. Our technologies facilitate the identification of DNA variants, RNA expression profiles, protein abundance, and metabolite changes associated with key CRS pathways, including immune cell activation, cytokine signaling, and inflammatory cascades. By integrating multi-omics data, we provide a holistic view of disease mechanisms and molecular interactions relevant to CRS.
Candidate Validation: Protheragen applies rigorous validation strategies to prioritize biomarker candidates associated with Cytokine Release Syndrome pathophysiology. Our process includes preliminary screening in relevant biological models, assessment of candidate expression or activity in CRS-relevant contexts, and evaluation of mechanistic associations with immune activation and cytokine signaling. Criteria for promising candidates include reproducibility, specificity to CRS-related pathways, and potential utility in monitoring therapeutic effects or disease progression.
Diverse Technological Platforms: Our biomarker assay development capabilities encompass a broad range of platforms tailored to the specific needs of CRS research. We offer custom assay development, adapting platforms such as immunoassays, mass spectrometry, flow cytometry, molecular diagnostics, and imaging technologies. These platforms are optimized for sensitivity, specificity, and scalability to support diverse biomarker analysis requirements.
Immunoassays: We utilize ELISA, chemiluminescent assays, and multiplex bead-based platforms for quantitative measurement of cytokines and immune mediators.
Mass Spectrometry: High-sensitivity LC-MS/MS workflows enable precise quantification and characterization of proteins and peptides relevant to CRS.
Flow Cytometry: Multiparametric flow cytometry is employed for cellular phenotyping, detection of surface or intracellular markers, and analysis of immune cell activation states.
Molecular Diagnostics: We offer qPCR, digital PCR, and RNA expression profiling to assess gene-level biomarkers and cytokine mRNA signatures.
Histopathology And Imaging: Tissue-based biomarker assessment is supported by immunohistochemistry, digital pathology, and advanced imaging modalities for spatial and contextual analysis.
Rigorous Method Validation: All analytical methods developed at Protheragen undergo rigorous validation according to established guidelines, including assessment of accuracy, precision, sensitivity, specificity, linearity, and reproducibility. Comprehensive quality control measures are implemented at every stage, ensuring reliable performance characteristics and reproducible results across preclinical studies.
We provide robust quantitative analysis capabilities for biomarker measurement, leveraging validated assays and advanced data analytics. Our protocols ensure accurate quantification of biomarker levels in a variety of sample matrices, supporting data-driven decision-making in CRS drug discovery.
Sample Analysis: Protheragen handles a wide range of sample types, including serum, plasma, cell culture supernatants, and tissue lysates, applying standardized protocols for sample processing and analysis. Stringent quality control procedures are in place to maintain sample integrity and ensure the reliability of analytical results.
High Throughput Capabilities: Our high-throughput analytical platforms enable multiplexed measurement of multiple biomarkers simultaneously, maximizing efficiency and conserving valuable samples. This approach accelerates data acquisition and enhances the statistical power of preclinical studies in CRS research.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| C-C motif chemokine ligand 8 (CCL8) | C-C motif chemokine ligand 8 (CCL8), also known as monocyte chemotactic protein 2 (MCP-2), is a member of the CC chemokine family. It is primarily involved in the regulation of immune cell trafficking by acting as a chemoattractant for various leukocyte subsets, including monocytes, lymphocytes, eosinophils, and basophils. CCL8 exerts its effects by binding to several chemokine receptors, such as CCR1, CCR2, and CCR5, on the surface of target cells. Through these interactions, CCL8 plays a role in mediating inflammatory responses, immune surveillance, and host defense against pathogens. It is produced by a variety of cell types, including monocytes, fibroblasts, and endothelial cells, particularly in response to pro-inflammatory stimuli. | CCL8 has been studied as a biomarker in a range of inflammatory and immune-mediated conditions. Elevated levels of CCL8 have been reported in biological fluids and tissues from patients with diseases such as rheumatoid arthritis, systemic lupus erythematosus, and certain infections. Its expression has also been investigated in the context of tumor microenvironments and fibrotic diseases. Measurement of CCL8 concentrations can provide information about the presence and extent of inflammation or immune activation in these settings. |
| C-X-C motif chemokine ligand 10 (CXCL10) | C-X-C motif chemokine ligand 10 (CXCL10), also known as interferon gamma-induced protein 10 (IP-10), is a small secreted chemokine belonging to the CXC chemokine family. It is primarily produced by several cell types, including monocytes, endothelial cells, and fibroblasts, in response to interferon-gamma and other pro-inflammatory stimuli. CXCL10 binds to the CXCR3 receptor on the surface of immune cells, such as T lymphocytes, natural killer cells, and dendritic cells, mediating their chemotactic migration to sites of inflammation. Through this mechanism, CXCL10 plays a key role in the regulation of immune cell trafficking, promotion of Th1-type immune responses, and modulation of inflammation during infection, autoimmune disease, and tumor immunity. | CXCL10 has been studied as a biomarker in various clinical contexts due to its association with inflammatory and immune responses. Elevated levels of CXCL10 in blood, cerebrospinal fluid, or tissue samples have been reported in infectious diseases (such as viral hepatitis, HIV, and COVID-19), autoimmune disorders (including multiple sclerosis and systemic lupus erythematosus), and certain cancers. Measurement of CXCL10 concentrations has been used in research to assess disease activity, monitor therapeutic response, and evaluate prognosis in these conditions. |
| TNF receptor superfamily member 1B (TNFRSF1B) | TNF receptor superfamily member 1B (TNFRSF1B), also known as TNFR2 or CD120b, is a cell surface receptor primarily for tumor necrosis factor alpha (TNF-α). TNFRSF1B is predominantly expressed on immune cells such as regulatory T cells, endothelial cells, and certain neuronal populations. Upon binding TNF-α, TNFRSF1B mediates signal transduction pathways that can lead to cell survival, proliferation, and immune modulation. Unlike TNFRSF1A (TNFR1), TNFRSF1B lacks a death domain and is more closely associated with anti-apoptotic and tissue repair responses. Its intracellular signaling involves the recruitment of TRAF proteins, leading to activation of NF-κB and MAPK pathways, which are important for inflammation regulation, immune response, and cell differentiation. | TNFRSF1B has been studied as a biomarker in various clinical contexts, particularly in inflammatory and autoimmune diseases. Its soluble form (sTNFR2) can be detected in plasma or serum, and levels have been reported to correlate with disease activity or severity in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and certain cancers. Measurement of TNFRSF1B or its soluble form is used in research to assess immune activation, inflammation status, and therapeutic response. |
| colony stimulating factor 2 (CSF2) | Colony stimulating factor 2 (CSF2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF), is a cytokine that plays a critical role in hematopoiesis by stimulating the proliferation, differentiation, and survival of hematopoietic progenitor cells. CSF2 primarily acts on granulocyte and macrophage precursors, promoting their maturation and function. It is produced by various cell types, including T cells, macrophages, endothelial cells, and fibroblasts, in response to immune stimuli. CSF2 is also involved in modulating immune responses, enhancing the functional activity of mature granulocytes and macrophages, and participating in inflammatory processes by promoting the production of other cytokines and mediators. | CSF2 has been investigated as a biomarker in several clinical contexts, particularly in diseases characterized by immune dysregulation or inflammation. Elevated levels of CSF2 have been reported in inflammatory and autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, as well as in certain malignancies, including hematological cancers. Measurement of CSF2 concentrations in biological fluids has been used in research to assess disease activity, monitor therapeutic responses, and explore its association with disease prognosis. |
| interferon gamma (IFNG) | Interferon gamma (IFNG) is a cytokine that plays a central role in innate and adaptive immunity. It is primarily produced by activated T lymphocytes, particularly Th1 cells, as well as natural killer (NK) cells. IFNG exerts its effects by binding to the interferon gamma receptor, leading to the activation of the JAK-STAT signaling pathway. This cytokine is a key mediator of macrophage activation, enhances antigen presentation by upregulating major histocompatibility complex (MHC) class I and II molecules, and promotes the differentiation of naive T cells into Th1 cells. IFNG also has antiviral, immunoregulatory, and anti-proliferative properties, and is involved in the regulation of various immune responses, including the inhibition of viral replication and modulation of cellular immunity. | IFNG has been used as a biomarker to assess cell-mediated immune responses, particularly in the context of infectious diseases, autoimmune disorders, and immunotherapy. Measurement of IFNG production, either at the protein or mRNA level, is commonly utilized in assays such as the interferon gamma release assay (IGRA) for the detection of latent or active Mycobacterium tuberculosis infection. Additionally, IFNG levels have been evaluated in the monitoring of immune activation or dysregulation in conditions such as chronic viral infections, inflammatory diseases, and certain cancers. Its expression can serve as an indicator of Th1-type immune responses. |
| interleukin 1 beta (IL1B) | Interleukin 1 beta (IL1B) is a pro-inflammatory cytokine produced primarily by activated macrophages, monocytes, and other immune cells. It is synthesized as an inactive precursor (pro-IL1B) that is cleaved by caspase-1 into its active form. IL1B plays a central role in the regulation of immune and inflammatory responses by promoting the expression of adhesion molecules, chemokines, and other cytokines. It is involved in the activation of lymphocytes, induction of fever, and mediation of cellular responses to infection, injury, or other inflammatory stimuli. Through its receptor, IL1B activates intracellular signaling pathways such as NF-κB and MAPK, leading to the transcription of genes involved in inflammation and immune defense. | IL1B is used as a biomarker to assess inflammation and immune activation in various clinical contexts. Elevated levels of IL1B in blood, tissue, or other biological fluids have been associated with inflammatory diseases such as rheumatoid arthritis, sepsis, and inflammatory bowel disease, as well as infections and certain cancers. Measurement of IL1B can aid in the evaluation of disease activity, monitoring of treatment response, and investigation of inflammatory processes in research and clinical studies. |
| interleukin 2 (IL2) | Interleukin 2 (IL2) is a cytokine produced primarily by activated CD4+ T lymphocytes. It plays a central role in the regulation of immune responses by promoting the proliferation, differentiation, and survival of T cells, B cells, natural killer (NK) cells, and monocytes. IL2 is critical for the development and maintenance of regulatory T cells (Tregs), which are essential for immune tolerance and prevention of autoimmunity. In addition, IL2 signaling contributes to the activation-induced cell death of T cells, which helps maintain immune homeostasis. Its biological effects are mediated through binding to the high-affinity IL2 receptor complex composed of CD25 (IL2RA), CD122 (IL2RB), and CD132 (IL2RG). | IL2 has been utilized as a biomarker in various clinical and research settings to assess immune activation and function. Measurement of IL2 protein levels or gene expression in serum, plasma, or cell culture supernatants is commonly performed to evaluate T cell activation status, monitor immune responses to infections, and assess the efficacy of immunotherapies. Changes in IL2 levels have been associated with immune-related disorders, including autoimmune diseases, transplant rejection, and certain cancers. Additionally, IL2 is sometimes measured as part of cytokine panels to characterize immune profiles in different pathological conditions. |
| interleukin 2 receptor subunit alpha (IL2RA) | Interleukin 2 receptor subunit alpha (IL2RA), also known as CD25, is a component of the high-affinity interleukin-2 (IL-2) receptor complex. IL2RA is predominantly expressed on activated T lymphocytes, regulatory T cells (Tregs), and some B cells. It binds to IL-2 in conjunction with the IL2RB (CD122) and IL2RG (CD132) subunits, facilitating the formation of a high-affinity receptor that transduces signals critical for T cell proliferation, survival, and differentiation. IL2RA expression is upregulated upon lymphocyte activation, and its presence is essential for the development and maintenance of immune tolerance mediated by Tregs. | IL2RA is used as a biomarker to assess immune activation and regulation. Its soluble form (sIL2RA) can be measured in serum or plasma and is utilized in the monitoring of immune-mediated conditions such as autoimmune diseases, graft-versus-host disease, and certain hematological malignancies. Elevated levels of IL2RA or sIL2RA are associated with increased T cell activation and may reflect disease activity or response to therapy in specific clinical contexts. |
| interleukin 6 (IL6) | Interleukin 6 (IL6) is a multifunctional cytokine produced by a variety of cell types, including T cells, B cells, macrophages, fibroblasts, and endothelial cells. It plays a central role in the regulation of immune responses, acute phase reactions, hematopoiesis, and inflammation. IL6 is a key mediator of the acute phase response in the liver, stimulating the production of acute phase proteins such as C-reactive protein (CRP) and fibrinogen. It also influences the differentiation and activation of immune cells, supports B cell maturation and antibody production, and modulates the balance between pro-inflammatory and anti-inflammatory signaling. IL6 signaling occurs through binding to its receptor complex, which activates the JAK/STAT pathway, leading to transcription of target genes involved in immune regulation and inflammation. | IL6 is widely measured as a biomarker of inflammation and immune activation. Elevated levels of IL6 in blood or other biological fluids are associated with various inflammatory and autoimmune conditions, including rheumatoid arthritis, sepsis, and certain infections. IL6 concentrations are also used in clinical and research settings to monitor disease activity, assess the severity of inflammatory states, and evaluate the response to therapeutic interventions. In addition, increased IL6 levels have been observed in some cancers and are associated with disease progression and prognosis in specific contexts. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF) is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as other immune cells such as T lymphocytes and natural killer cells. TNF plays a central role in the regulation of immune responses, inflammation, and apoptosis. It exerts its effects by binding to TNF receptors (TNFR1 and TNFR2) on target cells, leading to the activation of intracellular signaling pathways such as NF-κB and MAPKs. These pathways result in the expression of genes involved in inflammation, cell survival, and cell death. TNF is involved in host defense against infections, the modulation of immune cell activity, and the pathogenesis of various inflammatory and autoimmune diseases. | TNF levels have been measured in biological fluids such as serum, plasma, and synovial fluid in clinical and research settings. Elevated TNF concentrations have been associated with a variety of inflammatory and autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, and sepsis. TNF has been used as a biomarker to assess the presence and severity of inflammation, to monitor disease progression, and to evaluate responses to anti-TNF therapies in certain conditions. |
Explore Research Opportunities with Protheragen. Our biomarker research services offer comprehensive support for exploratory and preclinical studies in Cytokine Release Syndrome. We provide advanced analytical platforms and scientific expertise to facilitate the identification, characterization, and validation of research biomarkers relevant to CRS drug discovery. Please note that all biomarkers discussed are research targets only; we do not claim any as validated or mandatory for any application. Our services are focused exclusively on preclinical research stages, maintaining scientific objectivity and rigor throughout the process.
We invite you to connect with Protheragen to discuss collaborative opportunities in biomarker research for Cytokine Release Syndrome. Our team is committed to advancing scientific knowledge through exploratory research and open collaboration. Please reach out to explore how our expertise can support your preclinical research objectives.
Make Order
Experimental Scheme
Implementation
Conclusion
